WO2004044587A3 - Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 5 (edg5) - Google Patents

Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 5 (edg5) Download PDF

Info

Publication number
WO2004044587A3
WO2004044587A3 PCT/EP2003/012122 EP0312122W WO2004044587A3 WO 2004044587 A3 WO2004044587 A3 WO 2004044587A3 EP 0312122 W EP0312122 W EP 0312122W WO 2004044587 A3 WO2004044587 A3 WO 2004044587A3
Authority
WO
WIPO (PCT)
Prior art keywords
edg5
diseases
sphingolipid
therapeutics
diagnostics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/012122
Other languages
French (fr)
Other versions
WO2004044587A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to AU2003301991A priority Critical patent/AU2003301991A1/en
Priority to EP03810956A priority patent/EP1597580A2/en
Publication of WO2004044587A2 publication Critical patent/WO2004044587A2/en
Publication of WO2004044587A3 publication Critical patent/WO2004044587A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a human EDG5 which is associated with the cardio-vascular diseases, disorders of the gastroenterology system, reproduction diseases, disorders of the peripheral and central nervous system and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardio-vascular diseases, disorders of the gastroenterology system, reproduction diseases, disorders of the peripheral and central nervous system and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of EDG5 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2003/012122 2002-11-13 2003-10-31 Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 5 (edg5) Ceased WO2004044587A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003301991A AU2003301991A1 (en) 2002-11-13 2003-10-31 Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 5 (edg5)
EP03810956A EP1597580A2 (en) 2002-11-13 2003-10-31 Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 5 (edg5)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02025098 2002-11-13
EP02025098.1 2002-11-13

Publications (2)

Publication Number Publication Date
WO2004044587A2 WO2004044587A2 (en) 2004-05-27
WO2004044587A3 true WO2004044587A3 (en) 2004-09-23

Family

ID=32309327

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/012122 Ceased WO2004044587A2 (en) 2002-11-13 2003-10-31 Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 5 (edg5)

Country Status (3)

Country Link
EP (1) EP1597580A2 (en)
AU (1) AU2003301991A1 (en)
WO (1) WO2004044587A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014139883A1 (en) * 2013-03-14 2014-09-18 Galapagos Nv Molecular targets and compounds, and methods to identify the same, useful in the treatment of fibrotic diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057126A (en) * 1997-12-24 2000-05-02 Allelix Biopharmaceuticals, Inc. Mammalian EDG-5 receptor homologs
WO2000056135A2 (en) * 1999-03-23 2000-09-28 The Regents Of The University Of California Human polypeptide receptors for lysophospholipids and sphingolipids and nucleic acids encoding the same
WO2001081573A1 (en) * 2000-04-26 2001-11-01 Aventis Pharma Deutschland Gmbh Edg8 receptor, its preparation and use
US20020155512A1 (en) * 2001-04-18 2002-10-24 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
WO2003051395A2 (en) * 2001-11-30 2003-06-26 Solvay Pharmaceuticals Gmbh Edg-receptor agonist for the treatment of hypertension

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057126A (en) * 1997-12-24 2000-05-02 Allelix Biopharmaceuticals, Inc. Mammalian EDG-5 receptor homologs
WO2000056135A2 (en) * 1999-03-23 2000-09-28 The Regents Of The University Of California Human polypeptide receptors for lysophospholipids and sphingolipids and nucleic acids encoding the same
WO2001081573A1 (en) * 2000-04-26 2001-11-01 Aventis Pharma Deutschland Gmbh Edg8 receptor, its preparation and use
US20020155512A1 (en) * 2001-04-18 2002-10-24 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
WO2003051395A2 (en) * 2001-11-30 2003-06-26 Solvay Pharmaceuticals Gmbh Edg-receptor agonist for the treatment of hypertension

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MAZURAIS D. ET AL.: "Cell type-specific localization of human cardiac S1P receptors.", J. HISTOCHEM. CYTOCHEM., vol. 50, no. 5, May 2002 (2002-05-01), pages 661 - 669, XP009028821 *
TAKUWA Y. ET AL.: "The Edg family G protein-coupled receptors for lysophospholipids: their signaling properties and biological activities.", J. BIOCHEM., vol. 131, June 2002 (2002-06-01), pages 767 - 771, XP009028822 *
TAMAMA K.-I. ET AL.: "Extracellular mechanism through the Edg family of receptors might be responsible for sphingosine-1-phosphate-induced regulation of DNA sysnthesis and migration of rat aortic smooth-muscle cells.", BIOCHEM. J., vol. 353, 2001, pages 139 - 146, XP002276002 *
TOMAN R.E. ET AL.: "Lysophospholipid receptors in the nervous system", NEUROCHEM. RES., vol. 27, no. 7-8, August 2002 (2002-08-01), pages 619 - 627, XP002260726 *

Also Published As

Publication number Publication date
AU2003301991A1 (en) 2004-06-03
EP1597580A2 (en) 2005-11-23
WO2004044587A2 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
WO2004042389A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
WO2003093816A3 (en) Diagnostics and therapeutics for diseases associated with oxytocin receptor (oxtr)
WO2005040828A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2004080373A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
WO2004008153A3 (en) Diagnostics and therapeutics for diseases associated with homo sapiens putative neurotransmitter receptor (pnr)
WO2004044587A3 (en) Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 5 (edg5)
WO2003095967A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
WO2004038405A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
WO2004044589A3 (en) Diagnostics and therapeutics for diseases associated with human endothelial differentiation, sphingolipid g-protein-coupled receptor 3 (edg3)
WO2003072122A3 (en) Diagnostics and therapeutics for diseases associated with endothelial differentiation lysophosphatic acid g-protein-coupled receptor 7 (edg7)
WO2004057328A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor 38 (gpr38)
WO2003096020A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
WO2004104577A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 4 (5-ht4)
WO2003083135A3 (en) Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2)
WO2004038421A3 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
WO2004048978A3 (en) Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37)
WO2004071392A8 (en) Diagnostics and therapeutics for diseases associated with acetylcholine receptor, muscarinic 4(m4)
WO2003100433A3 (en) Diagnostics and therapeutics for diseases associated with arginine vasopressin receptor 3 (avpr3)
WO2003100435A3 (en) Diagnostics and therapeutic use of neuromedin u receptor 2 (nmu2)
WO2004038407A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
WO2004042405A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)
WO2003081257A3 (en) Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 1 (npff1)
WO2004082566A3 (en) Diagnostics and therapeutics for diseases associated with complement component 3a receptor 1 (c3ar1)
WO2004015427A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 19 (gpr19)
WO2003100434A3 (en) Diagnostic and therapeutic use of the arginine vasopressin receptor 2 (avpr2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003810956

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003810956

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2003810956

Country of ref document: EP